A A Khorana

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi request reprint The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave, Box 704, Rochester, New York 14642, USA
    Oncologist 12:1361-70. 2007
  2. pmc Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States
    Alok A Khorana
    Division of Oncology Hematology, James P Wilmot Cancer Center, University of Rochester, Rochester, NY
    Clinicoecon Outcomes Res 5:101-8. 2013
  3. doi request reprint Cancer-associated thrombosis: updates and controversies
    Alok A Khorana
    James P Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, NY, USA
    Hematology Am Soc Hematol Educ Program 2012:626-30. 2012
  4. doi request reprint Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States
    Alok A Khorana
    Department of Medicine, University of Rochester and James P Wilmot Cancer Center, Rochester, NY 14642, USA
    Cancer 119:648-55. 2013
  5. doi request reprint Risk assessment for cancer-associated thrombosis: what is the best approach?
    Alok A Khorana
    James P Wilmot Cancer Center, and Department of Medicine, University of Rochester, Rochester, NY, USA
    Thromb Res 129:S10-5. 2012
  6. pmc Cancer and coagulation
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, New York, USA
    Am J Hematol 87:S82-7. 2012
  7. pmc Development and validation of a predictive model for chemotherapy-associated thrombosis
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, NY, USA
    Blood 111:4902-7. 2008
  8. pmc Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer
    Alok A Khorana
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York, USA
    Arch Intern Med 168:2377-81. 2008
  9. doi request reprint Cancer and thrombosis: implications of published guidelines for clinical practice
    A A Khorana
    Division of Hematology Oncology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Ann Oncol 20:1619-30. 2009
  10. pmc Assessing risk of venous thromboembolism in the patient with cancer
    Alok A Khorana
    James P Wilmot Cancer Center, and Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 27:4839-47. 2009

Detail Information

Publications41

  1. ncbi request reprint The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave, Box 704, Rochester, New York 14642, USA
    Oncologist 12:1361-70. 2007
    ..Multifaceted active educational and electronic interventions are necessary to raise awareness and reduce the burden of cancer-associated thrombosis and its attendant consequences...
  2. pmc Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States
    Alok A Khorana
    Division of Oncology Hematology, James P Wilmot Cancer Center, University of Rochester, Rochester, NY
    Clinicoecon Outcomes Res 5:101-8. 2013
    ..This study examines venous thromboembolism (VTE)-associated resource utilization and real-world costs in ambulatory patients initiating chemotherapy for selected common high-risk solid tumors...
  3. doi request reprint Cancer-associated thrombosis: updates and controversies
    Alok A Khorana
    James P Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, NY, USA
    Hematology Am Soc Hematol Educ Program 2012:626-30. 2012
    ..Selecting the appropriate patients for prophylaxis, however, continues to be a matter of controversy...
  4. doi request reprint Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States
    Alok A Khorana
    Department of Medicine, University of Rochester and James P Wilmot Cancer Center, Rochester, NY 14642, USA
    Cancer 119:648-55. 2013
    ..Therefore, the authors examined the incidence and predictors of VTE in ambulatory patients with bladder, colorectal, lung, ovary, pancreas, or gastric cancers...
  5. doi request reprint Risk assessment for cancer-associated thrombosis: what is the best approach?
    Alok A Khorana
    James P Wilmot Cancer Center, and Department of Medicine, University of Rochester, Rochester, NY, USA
    Thromb Res 129:S10-5. 2012
    ..Targeted thromboprophylaxis provides an optimal risk-benefit ratio and the best opportunity to reduce the burden of VTE and its consequences for patients with cancer...
  6. pmc Cancer and coagulation
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, New York, USA
    Am J Hematol 87:S82-7. 2012
    ..Treatment of cancer-associated thrombosis requires long-term anticoagulation with LMWH. Results from ongoing and planned trials of novel anticoagulants in the cancer setting are awaited...
  7. pmc Development and validation of a predictive model for chemotherapy-associated thrombosis
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, NY, USA
    Blood 111:4902-7. 2008
    ..5 months (C-statistic = 0.7 for both cohorts). This model can identify patients with a nearly 7% short-term risk of symptomatic VTE and may be used to select cancer outpatients for studies of thromboprophylaxis...
  8. pmc Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer
    Alok A Khorana
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York, USA
    Arch Intern Med 168:2377-81. 2008
    ..Anemia is frequent in patients with cancer, but there are concerns regarding treatment with erythropoiesis-stimulating agents. Blood transfusions are commonly used as an alternative, but with little data regarding outcomes...
  9. doi request reprint Cancer and thrombosis: implications of published guidelines for clinical practice
    A A Khorana
    Division of Hematology Oncology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Ann Oncol 20:1619-30. 2009
    ..Improved adherence to guidelines could substantially reduce morbidity, decrease resource use, enhance quality of life, and improve survival in these patients...
  10. pmc Assessing risk of venous thromboembolism in the patient with cancer
    Alok A Khorana
    James P Wilmot Cancer Center, and Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 27:4839-47. 2009
    ..Patients with cancer are increasingly at risk for venous thromboembolism (VTE). Rates of VTE, however, vary markedly among patients with cancer...
  11. pmc Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action
    Alok A Khorana
    James P Wilmot Cancer Center, and Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 27:4919-26. 2009
    ..Venous thromboembolism (VTE) is an increasingly frequent complication of cancer and its treatments, and is associated with worsened mortality and morbidity in patients with cancer...
  12. pmc Venous thromboembolism and prognosis in cancer
    Alok A Khorana
    James P Wilmot Cancer Center, and the Department of Medicine, University of Rochester, Rochester, NY 14642, USA
    Thromb Res 125:490-3. 2010
    ..This review focuses on the clinical evidence documenting a link between VTE and adverse short-term and long-term prognosis in patients with cancer...
  13. ncbi request reprint Risk assessment and prophylaxis for VTE in cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center, and the Department of Medicine, University of Rochester, New York, USA
    J Natl Compr Canc Netw 9:789-97. 2011
    ..This article focuses on recent and ongoing studies of risk assessment and prophylaxis in patients with cancer...
  14. ncbi request reprint Concordance: how does a physician who is neither black nor white decide when race is a factor?
    Alok A Khorana
    Department of Medicine, University of Rochester, New York, USA
    Health Aff (Millwood) 24:511-5. 2005
  15. ncbi request reprint Approaches to risk-stratifying cancer patients for venous thromboembolism
    Alok A Khorana
    James P Wilmot Cancer Center, and the Department of Medicine, University of Rochester, Rochester, NY, USA
    Thromb Res 120:S41-50. 2007
    ..Finally, we discuss model-based approaches to risk-stratifying cancer patients that incorporate the known multiple risk factors for VTE and can help identify high-risk subgroups in the cancer population...
  16. ncbi request reprint Pancreatic cancer and thromboembolic disease
    Alok A Khorana
    James P Wilmot Cancer Center, University of Rochester, NY 14642, USA
    Lancet Oncol 5:655-63. 2004
    ..Further research is needed to understand better the morbidity and mortality associated with this disease in pancreatic cancer and to optimise strategies of prevention and treatment...
  17. ncbi request reprint Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, New York 14642, USA
    Cancer 110:2339-46. 2007
    ..In the current study, the frequency, risk factors, and trends associated with VTE were examined among hospitalized cancer patients...
  18. ncbi request reprint Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY 14642, and the National Human Genomics Research Institute, National Institutes of Health, Bethesda, MD, USA
    J Gastrointest Surg 9:903-11. 2005
    ..Adjuvant therapy may have both antiangiogenic and cytotoxic effects. Addition of anti-VEGF agents to adjuvant regimens may further improve outcomes...
  19. ncbi request reprint Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis
    Alok A Khorana
    The James P Wilmot Cancer Center and the Department of Medicine, University of Rochester Medical Center, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Cancer 97:960-8. 2003
    ....
  20. ncbi request reprint Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer
    Alok A Khorana
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York 14642, USA
    Clin Cancer Res 13:2870-5. 2007
    ..We correlated TF expression with vascular endothelial growth factor (VEGF) expression, microvessel density, and venous thromboembolism in resected pancreatic cancer...
  21. ncbi request reprint Thromboembolism in hospitalized neutropenic cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 24:484-90. 2006
    ..We investigated venous and arterial thromboembolism and associated outcomes in hospitalized cancer patients actively receiving therapy, as identified by neutropenia...
  22. doi request reprint Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer
    G C Connolly
    Department of Hematology and Oncology, University of Rochester, Rochester, NY 14642, USA
    Lung Cancer 78:253-8. 2012
    ..The incidence and economic impact of lung cancer-associated venous thromboembolic (VTE) events in a contemporary ambulatory setting is unknown...
  23. doi request reprint Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer
    Laurel A Menapace
    James P Wilmot Cancer Center, and Department of Medicine, University of Rochester, Rochester, New York, USA
    Thromb Haemost 106:371-8. 2011
    ..The role of anticoagulation in treating incidental or visceral VTE warrants further study...
  24. doi request reprint Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model
    Rohit Sud
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, NY, USA
    Thromb Res 123:S18-21. 2009
    ..VTE is associated with mortality, morbidity, potential delay in treatments for cancer and consumption of scarce health-care resources. Hence, reducing VTE with targeted prophylaxis could improve outcomes for cancer patients...
  25. pmc New insights into cancer-associated thrombosis
    Tarek Sousou
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, NY, USA
    Arterioscler Thromb Vasc Biol 29:316-20. 2009
    ..Long-term anticoagulation with LMWH is safe and effective in reducing recurrent VTE in cancer. The role of thromboprophylaxis in ambulatory cancer patients receiving chemotherapy is an area of active investigation...
  26. doi request reprint Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study
    Jorge L Yao
    Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA jorge
    Cancer Invest 27:430-4. 2009
    ..001). Our findings reinforce the link between angiogenesis and TF expression in PCa. We suggest further exploration of TF-mediated pathways leading to increased tumor aggressiveness in PCa, and the possible use of anti-TF agents in PCa...
  27. ncbi request reprint A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications
    Nicole M Kuderer
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
    Cancer 110:1149-61. 2007
    ....
  28. pmc FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis
    Abha Sahni
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Blood 107:126-31. 2006
    ..These results demonstrate that binding of FGF-2 to fibrin(ogen) mediated by the 5-residue FGF-2-fibrin(ogen) interactive site is required for augmented angiogenesis...
  29. ncbi request reprint Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, New York, USA
    Cancer 104:2822-9. 2005
    ..The incidence of venous thromboembolism (VTE) is increased in cancer, but little information is available about risk factors in cancer patients on chemotherapy...
  30. pmc The role of thromboprophylaxis in cancer patients: emerging data
    Laurel A Menapace
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York 14642, USA
    Curr Opin Hematol 17:450-6. 2010
    ..A significant proportion of cancer-associated VTE occurs in the ambulatory setting and is associated with poorer outcomes and reduced survival. Risk for VTE is influenced by patient, cancer and treatment-specific factors...
  31. ncbi request reprint Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight
    Alok A Khorana
    James P Wilmot Cancer Center and Hematology Oncology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY14642, USA
    Arterioscler Thromb Vasc Biol 23:2110-5. 2003
    ..Tumors depend on an expanding vasculature, and heparins may affect vessel growth and function. We investigated the effect of heparins differing in Mr on selected endothelial cell properties...
  32. pmc Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma
    Gregory C Connolly
    Department of Medicine, University of Rochester, Rochester, NY, USA
    Thromb Res 122:299-306. 2008
    ..Hepatocellular carcinoma (HCC) is commonly associated with portal vein thrombosis (PVT). Little is known about factors predictive for PVT in patients with HCC or its correlation with systemic venous thromboembolism (VTE)...
  33. doi request reprint Cancer patients and awareness of venous thromboembolism
    Tarek Sousou
    James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, Minnesota 14642, USA
    Cancer Invest 28:44-5. 2010
    ..This study reveals an alarming lack of knowledge amongst patients regarding the increased risk of thrombosis. Informed patients are willing to use prophylaxis, if its effectiveness is established...
  34. ncbi request reprint Malignancy, thrombosis and Trousseau: the case for an eponym
    A A Khorana
    James P Wilmot Cancer Center, and Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Thromb Haemost 1:2463-5. 2003
  35. ncbi request reprint The influence of host response on colorectal cancer prognosis
    Leo Shunyakov
    James P Wilmot Cancer Center and Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Clin Colorectal Cancer 4:38-45. 2004
    ..The influence of the host response to CRC needs confirmation in prospective studies, but in the meantime should be part of risk stratification. Novel approaches to further augmenting this response merit study...
  36. pmc Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy
    Gregory C Connolly
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, NY, USA
    Thromb Res 126:113-8. 2010
    ..Leukocytosis has been associated with thrombosis and mortality in cancer patients. We explored the association of leukocytosis with venous thromboembolism (VTE) and early mortality in cancer patients initiating chemotherapy...
  37. ncbi request reprint American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
    Gary H Lyman
    Duke University Medical Center, University of Rochester Medical Center, Rochester, USA
    J Clin Oncol 25:5490-505. 2007
    ..To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer...
  38. doi request reprint Risk stratification for cancer-associated venous thromboembolism
    Gregory C Connolly
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
    Best Pract Res Clin Haematol 22:35-47. 2009
    ..This model-based approach may have a significant impact on cancer-related morbidity, mortality and cost of care by directing targeted thromboprophylaxis in the future...
  39. doi request reprint Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score
    Gregory C Connolly
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, N Y, USA
    Thromb Res 125:S1-7. 2010
    ..Targeted thromboprophylaxis utilizing model-based and/or biomarker-based approaches may provide an optimal risk-benefit ratio and is currently the focus of ongoing clinical trials...
  40. ncbi request reprint Venous thromboembolism in patients with diffuse large B-cell lymphoma
    Rami S Komrokji
    Department of Medicine, University of Cincinnati and Cincinnati Veterans Administration Medical Center, Cincinnati, OH 45267 0501, USA
    Leuk Lymphoma 47:1029-33. 2006
    ..2 years (95% CI 1.8 - 8.6) for those without VTE (P = 0.038). We conclude that VTE is a frequent complication of DLBCL that occurs particularly at diagnosis and during initial therapy, and it is associated with a worse prognosis...
  41. ncbi request reprint Variation in the cost of medications for the treatment of colorectal cancer
    Salvatore A Ferro
    College of Pharmacy, Union University, Albany, NY, USA
    Am J Manag Care 14:717-25. 2008
    ..To evaluate the economic burden of colorectal cancer (CRC) treatment on the healthcare system as treatment costs have risen 340-fold during the past 5 years...